Study:
Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing`s Syndrome
Rationale:
n/a
Purpose:
This is a compassionate use study. In addition to providing compassionate use access to
mifepristone, objectives of the study will be to evaluate the safety and utility of
mifepristone in the treatment of the signs and symptoms of endogenous Cushing`s syndrome
when given on a compassionate use basis. The study will only enroll subjects whose
physicians have determined that medical treatment is needed to control the symptoms or signs
of hypercortisolemia.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
Cushing`s Disease
Cushing`s Syndrome |
Drug: Mifepristone |
Phase 3 |
Verified by
Corcept Therapeutics
October, 2011
Sponsored by: Corcept Therapeutics
Information provided by: Corcept Therapeutics
ClinicalTrials.gov identifier: NCT01371565
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Coleman Gross, M.D.., Study Director